CTRI/2019/04/018581
Not yet recruiting
Phase 4
Effectiveness and safety of 0.5% Timolol aqueous solution in treatment of pyogenic granuloma - multicentic, randomized, double-blind, placebo controlled pilot study
Indian Association of Dermatologists Venereologists and Leprologists Research grant0 sites0 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Indian Association of Dermatologists Venereologists and Leprologists Research grant
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •i.Clinically diagnosed cases of pyogenic granuloma over skin
- •ii.Age 2 years to 65 years
- •iii.Patients consenting/ assenting to participate in the trial and come for follow â?? up visits
- •iv.Duration of skin lesion not more than 8 weeks
Exclusion Criteria
- •i.Age less than 2 years or more than 65 years
- •ii.Mucosal pyogenic granuloma
- •iii.Pregnant or lactating patients
- •iv.Systemic comorbidities like cardiac problems (sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure, cardiogenic shock), bronchial asthma, COPD, persistent hypoglycemia
- •v.Patient on systemic beta\-blockers, calcium channel blockers, quinidine, which have a significant interaction with topical timolol.
- •vi.Use of any other treatment modality previously
Investigators
Similar Trials
Recruiting
Phase 3
The efficacy and safety of 0.5% topical timolol on corneometry and transepidermal water loss after ablative fractional CO2 laser for atrophic acne scars: a split face randomized double blind placebo-controlled trialWe considered that timolol may have an effect in wound healing promotion in patients who undergo AFCO2 resurfacing. Our study aimed to investigate the efficacy and safety of 0.5% topical timolol maleaTCTR20190722005none25
Active, not recruiting
Not Applicable
THE EFFICACY AND SAFETY OF TIMOLOL MALEATE 0.5% COMPARED TO BRINZOLAMIDE 1% EACH GIVEN TWICE DAILY WHEN ADDED TO TRAVOPROST 0.004% GIVEN EACH EVENING IN PRIMARY OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSIVE PATIENTSIncreased intraocular pressure and glaucomaEUCTR2005-004201-29-HUAlcon Hungarian ltd170
Recruiting
Phase 1
Efficacy and safety of 0.15% Thiamidol combination with hyaluronic acid versus 0.15%Thiamidol or hyaluronic acid alone in treatment of melasma : A randomized single-blind trialMelasma is acquired light to dark-brown poorly circumscribed maculees. It's mainly seen in premenopausal women. The etiology of melasma is the combination of genetic,hormonal and ultraviolet light exmelasmaTCTR20200710001Faculty of medicine, Thammasat university96
Withdrawn
Phase 2
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)Infantile HemangiomasNCT01408056Children's Hospital of Philadelphia
Completed
Phase 2
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)Infantile HemangiomaNCT02913612Kanecia Obie Zimmerman105